SEC Filings
Keurig Dr Pepper Seeks $2 Billion From Stock Sale To Pay Down Borrowings Before Split
The beverage and coffee company modeled leverage falling from approximately 4.1 times to 3.8 times after the offering and repayments.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The beverage and coffee company modeled leverage falling from approximately 4.1 times to 3.8 times after the offering and repayments.
SEC Filings
The new shares account for about 17% of the stated post-offering total, with initial liver-disease trial data expected in 2027.
Earnings
The 2027 outlook exceeds its 2026 revenue estimate, but fourth-quarter sales are expected to fall from a year earlier.
SEC Filings
CorMedix suspended its 2027 DefenCath sales outlook while keeping its 2026 revenue forecast at $325 million to $345 million.
SEC Filings
The retirement-services subsidiary's update comes alongside Apollo's financing for a previously announced investment.
SEC Filings
The ODG purchase takes commercial work from about 20% to 28% of revenue and adds performance-based employee awards.
Earnings
Product revenue rose 89% as international launches expanded the reach of its hormone replacement treatment.
SEC Filings
Long-term follow-up showed five of eight patients maintained functional cure, while three lost that status but stayed partial cures.
SEC Filings
Sales reached $269.3 million, but the operating loss widened to $34.2 million as expenses grew.
SEC Filings
Higher turnaround spending has produced uneven results, while management targets expanding margins in 2028 and double-digit returns in 2029.
SEC Filings
Liver-disease trials pushed development spending to $27.0 million, while the next FDA meeting is scheduled for December.
SEC Filings
Commercial-scale manufacturing validation is complete, with interim trial results and FDA pathway feedback expected in early 2027.